Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2023-10-30 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于回购公司部分股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding the company's plan to repurchase its own shares using its own funds, specifying the purpose, conditions, price range, quantity, funding source, implementation period, and risks associated with the share repurchase. It includes board meeting resolutions, independent director opinions, and compliance with regulatory requirements. The content focuses on the share buyback plan and related authorizations rather than financial results or earnings. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares. The document length and detail confirm it is the actual announcement of the share repurchase plan, not a brief notice or a report publication announcement.
2023-10-30 Chinese
关于2023年前三季度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to make asset impairment provisions for the first three quarters of 2023. It details the reasons, amounts, accounting standards, and approvals related to the impairment. The document is relatively short (3200 characters) and does not contain full financial statements or comprehensive financial data typical of an interim or annual report. Instead, it is a regulatory announcement about a specific accounting action taken during the period. There is no indication that this is a full quarterly or annual report, nor is it a certification or a simple notice of report publication. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2023-10-30 Chinese
关于收到公司控股股东、实际控制人、董事长提议公司回购股份的提示性公告
Transaction in Own Shares Classification · 100% confidence The document is a short announcement (1380 characters) regarding a proposal by the company's controlling shareholder and chairman to repurchase shares. It details the proposal's background, purpose, and parameters but does not contain financial statements or detailed financial data. It is clearly an announcement about a share repurchase plan, not the repurchase itself or a full financial report. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers announcements of share buybacks or sales by the company.
2023-10-25 Chinese
关于药石转债可能触发向下修正转股价格条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 南京药石科技股份有限公司 regarding a potential downward adjustment of the conversion price of its convertible bonds (药石转债). It details the bond issuance, listing, conversion price adjustment conditions, and the possible triggering of the downward adjustment clause. The document is an informative notice about a specific financing instrument and its terms, not a full financial report or earnings release. It does not contain financial statements or comprehensive financial analysis but rather a regulatory disclosure about bond terms and potential price adjustments. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-10-24 Chinese
关于公司股东减持计划提前终止的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding the early termination of a shareholder's planned share reduction (shareholder selling shares). It details the shareholder's original plan, the decision to terminate it early, and the current shareholding status. There is no financial report, earnings data, or management discussion. The content fits the category of a Transaction in Own Shares or shareholder shareholding changes. Since it concerns a shareholder's plan to reduce shares and its termination, it aligns best with the 'Transaction in Own Shares' category (POS). The document length is short and is a direct announcement, not a report or certification.
2023-10-16 Chinese
关于2023年第三季度可转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (可转债) conversion situation for the third quarter of 2023 by 南京药石科技股份有限公司. It details the bond issuance, listing, conversion price adjustments, and the actual conversion amounts and share changes during the quarter. The document includes specific financial figures related to bond conversions and share capital changes but does not present a full financial report or comprehensive financial statements. It is a regulatory announcement about capital structure changes due to convertible bond conversions, not a full capital/financing update or an earnings release. Given the detailed disclosure about bond conversion and share changes, this fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive data about financing activities, so it is not merely a report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2023-10-09 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.